NeuroBell

Name: NeuroBell
Brand: NeuroBell

AI Native

Medical device company developing newborn brain monitoring solutions.

Est 2022

LinkedIn 3K|Website|FTEs 19

Published Sep 2, 2026

01Common complaints

- If an organization needs an off-the-shelf, widely deployed solution immediately - Vendor pages indicate the product is not yet available for commercial sale in the EU or US; organizations requiring immediate deployment should consider established vendors with commercially available offerings. - If the organization requires published security/compliance artifacts before evaluation - NeuroBell does not publicly document SOC 2/ISO certifications, HIPAA/BAA readiness, or detailed cloud security architecture. - If the organization requires a large body of independent peer-reviewed performance data - Public third-party review and independent evidence are minimal compared with incumbents. - If the organization requires a full, multi-purpose EEG platform beyond neonatal bedside seizure monitoring - Established conventional EEG platforms may better support diverse modalities, higher channel counts, and long-standing workflows. - Current limitations acknowledged by the vendor - The vendor explicitly states: "Product not yet available for commercial sale in the EU or US." This limits immediate procurement in those jurisdictions. - Regulatory and roadmap notes - Funding announcements indicate the vendor is preparing for US regulatory submission (FDA), but a public FDA clearance identifier was not found in this research pass. - Scale and performance limits - Not publicly documented (e.g., maximum concurrent streams, retention, portal performance). - Security or compliance gaps - Public documentation on security certifications and privacy posture is limited or absent. - API and integration constraints - No public details on HL7/FHIR/EMR integration or APIs were found in this research pass.

Deal disqualifiers: what makes a poor fit

Sites requiring extensive published security/compliance artifacts, large bodies of independent peer-reviewed evidence, or immediate commercial availability.

02Why they buy

- Candidate distinguishing attributes (vendor-stated; require independent validation) - Design emphasis on neonatal use cases (headcap shaped for neonates and workflows intended for NICU staff). - A combined hardware and software approach: portable amplifier, neonatal headcap, and a web-based review portal intended to support bedside monitoring and alerting. - Unvalidated claims requiring further evidence - Real-world accuracy of automated neonatal seizure detection. - Demonstrated reductions in time-to-treatment, transfer avoidance, or improved clinical outcomes attributable to the system. - Areas where competitors have documented advantages - Ceribell: published regulatory clearances and vendor-published adoption figures in some markets. - Natus/Cadwell: established procurement pathways, service organizations, and comprehensive conventional EEG feature sets.

03Field reports

- Important limitation (high impact) - NeuroBell is a medical device company whose product pages indicate the product is not yet available for commercial sale in the EU or US. As a result, there is little to no mainstream review coverage on typical B2B review sites (G2/TrustRadius/Gartner Peer Insights) at the time of this research. - Gartner Peer Insights - No NeuroBell product listing was found in this research pass. - G2 - No credible NeuroBell listing or reviews were found in this research pass. - TrustRadius - No NeuroBell product listing or reviews were found in this research pass. - Community/social (Reddit / Hacker News) - No substantive discussions were found about NeuroBell’s neonatal EEG product specifically. Some search results for similar terms relate to unrelated items and should not be treated as product feedback. - What can be used as customer evidence now - Vendor or partner case study material exists (see Case Studies section), but these are not independent end-user reviews and should be treated as vendor-associated evidence.

Health Innovation Hub Ireland (HIHI) case study (vendor/partner ecosystem source)

A PDF titled "Neurobell - clinical evaluation case study" is available via HIHI (vendor/partner program material).
Critical evaluation: this is an innovation program case study rather than an independent peer-reviewed clinical outcomes paper. Reported benefits should be treated as directional unless the case study provides methodology, comparator groups, sample size, and statistically supported clinical endpoints.

UCC / institutional announcements as evidence

UCC announcements describe NeuroBell’s device as AI-powered and note funding and intended clinical trials/expansion.
Critical evaluation: university press releases are credible for funding and spin-out facts but are not sufficient to validate device performance or clinical effectiveness.

Vendor product claims that need independent validation

Statements such as automated neonatal seizure detection and neonatal-focused validation should be confirmed via clinical documentation, independent validation studies, and regulatory filings.

04Best fit

Organization sizes

Hospitals with NICUs, including community hospitals without round-the-clock neurophysiology coverage and tertiary centers seeking additional bedside monitoring capacity.

Industries and verticals

Neonatal and pediatric hospital care; perinatal networks; regional NICUs that depend on monitoring for transfer and treatment decisions.

Roles and personas

Decision makers: NICU medical director; neonatology leadership; neurology/neurocritical care leadership (for governance); biomedical/clinical engineering; hospital IT/security; procurement/value analysis committees.
End users: NICU nurses and neonatologists initiating monitoring; EEG technologists (if involved); pediatric neurologists reviewing EEG and responding to alerts.

Pain points and challenges the product addresses

Limited access to continuous EEG in NICUs because of staff availability and equipment complexity.
Delays in seizure identification when clinical signs are absent.

Qualification criteria: what makes a suitable fit

NICU units with documented gaps in EEG access and willingness to pilot new technology with clear clinical escalation protocols.

05The pitch

What the product does (core value proposition in objective terms)

- NeuroBell is developing a neonatal-focused EEG monitoring system composed of a portable/wireless amplifier, a web portal for EEG review, and a neonatal headcap intended for easier application in NICU settings. The system includes an automated neonatal seizure detection component that the vendor states will generate alerts. - The company describes the product as intended for continuous EEG monitoring at the bedside and positions it as an option for settings where neurophysiology specialists are not available on-site.

Target market and market positioning

Primary target: neonatal intensive care units (NICUs) and hospitals that want more frequent or continuous neonatal brain monitoring without needing specialist EEG setup or on-site interpretation.
Positioning: the vendor presents the product as providing access to clinical EEG data for NICU staff with a headcap and a simplified operational workflow and automated decision-support features.

Get a comprehensive analysis of NeuroBell including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →